Edwards Lifesciences Corporation (EW)
Edwards Lifesciences is a medical technology company that specialises in replacing damaged heart valves without the need for open-heart surgery.
Is Edwards Lifesciences Corporation a good stock for a UK beginner?
The honest version: Edwards Lifesciences is a medical technology company that specialises in replacing damaged heart valves without the need for open-heart surgery.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Dominance in the ageing population heart-care market
Significant changes to healthcare reimbursement policies
What does Edwards Lifesciences Corporation do?
The company focuses on patients with structural heart disease, creating advanced artificial valves and monitoring tools used in intensive care. Sales of these high-tech medical devices to hospitals and surgeons worldwide are what pay the bills. Their edge rests on how they continue to innovate in the heart-valve market to stay ahead of competitors while managing the high costs of medical research.
On our factor screen it looks strongest on quality and momentum, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 14% over the year
- ✓Very profitable - turns about 15% of sales into profit
- !High P/E of 52 - big growth is already priced in
- ✓Low debt - a sturdier balance sheet
- Quality screens high (81/100)
- High profit margins on specialised medical products
- Strong double-digit revenue growth
- Leading position in a niche, essential healthcare market
- Value screens low (24/100)
- Income screens low (16/100)
- Strict and unpredictable medical regulatory hurdles
- Potential for new medical technologies to disrupt current products
- Dependence on hospital budgets and government healthcare funding
What do Edwards Lifesciences Corporation's numbers mean?
How much money does Edwards Lifesciences Corporation make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Edwards Lifesciences Corporation pay a dividend?
No - Edwards Lifesciences Corporation doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Edwards Lifesciences Corporation report earnings, and how did recent quarters go?
Edwards Lifesciences Corporation is next scheduled to report on about 2026-10-29 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-23 | $0.74 | $0.78 | Beat +5% |
| 2026-04-23 | $0.73 | $0.78 | Beat +7% |
| 2026-02-10 | $0.62 | $0.58 | Missed -6% |
| 2025-10-30 | $0.59 | $0.67 | Beat +13% |
| 2025-07-24 | $0.62 | $0.67 | Beat +8% |
| 2025-04-23 | $0.60 | $0.64 | Beat +7% |
Across the last 6 quarters here, Edwards Lifesciences Corporation came in ahead of what analysts expected 5 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Edwards Lifesciences Corporation?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Edwards Lifesciences Corporation?
How many points the write-up makes each way — a balance check, not a score or verdict.
- High profit margins on specialised medical products
- Strong double-digit revenue growth
- Leading position in a niche, essential healthcare market
- No dividend payments for income-focused investors
- High valuation multiples compared to broader market averages
- Heavy reliance on a specific segment of heart surgery
- Strict and unpredictable medical regulatory hurdles
- Potential for new medical technologies to disrupt current products
- Dependence on hospital budgets and government healthcare funding
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained drop in revenue growth below industry averages
- Major safety recalls or clinical trial failures for key products
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.